ArticleHaematologica2012

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Katja Sockel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.